XOMA Corporation (XOMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
XOMA POWR Grades
- XOMA scores best on the Value dimension, with a Value rank ahead of 65.09% of US stocks.
- XOMA's strongest trending metric is Growth; it's been moving down over the last 177 days.
- XOMA ranks lowest in Growth; there it ranks in the 4th percentile.
XOMA Stock Summary
- XOMA CORP's stock had its IPO on April 5, 1989, making it an older stock than 89.9% of US equities in our set.
- The ratio of debt to operating expenses for XOMA CORP is higher than it is for about only 4.58% of US stocks.
- With a year-over-year growth in debt of -69.2%, XOMA CORP's debt growth rate surpasses just 3.37% of about US stocks.
- Stocks with similar financial metrics, market capitalization, and price volatility to XOMA CORP are RVP, LEV, IVDA, ORGS, and MC.
- XOMA's SEC filings can be seen here. And to visit XOMA CORP's official web site, go to www.xoma.com.
XOMA Valuation Summary
- In comparison to the median Healthcare stock, XOMA's price/sales ratio is 27.45% higher, now standing at 6.5.
- XOMA's price/earnings ratio has moved up 35 over the prior 243 months.
Below are key valuation metrics over time for XOMA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| XOMA | 2023-01-20 | 6.5 | 2.0 | 27.0 | 9.9 |
| XOMA | 2023-01-19 | 6.3 | 2.0 | 26.2 | 9.5 |
| XOMA | 2023-01-18 | 6.4 | 2.0 | 26.6 | 9.7 |
| XOMA | 2023-01-17 | 6.2 | 1.9 | 25.7 | 9.2 |
| XOMA | 2023-01-13 | 6.4 | 2.0 | 26.3 | 9.5 |
| XOMA | 2023-01-12 | 6.2 | 1.9 | 25.5 | 9.1 |
XOMA Growth Metrics
- Its year over year price growth rate is now at -42.77%.
- Its 5 year net cashflow from operations growth rate is now at 81.98%.
- Its 3 year cash and equivalents growth rate is now at 82.99%.
The table below shows XOMA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-09-30 | 40.486 | 21.653 | 9.793 |
| 2022-06-30 | 40.975 | 22.241 | 9.535 |
| 2022-03-31 | 40.893 | 22.583 | 12.043 |
| 2021-12-31 | 38.16 | 22.678 | 7.787 |
| 2021-09-30 | 29.797 | 9.714 | 5.429 |
| 2021-06-30 | 29.414 | 10.353 | 10.156 |
XOMA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- XOMA has a Quality Grade of C, ranking ahead of 66.13% of graded US stocks.
- XOMA's asset turnover comes in at 0.233 -- ranking 184th of 682 Pharmaceutical Products stocks.
- DARE, WINT, and TCON are the stocks whose asset turnover ratios are most correlated with XOMA.
The table below shows XOMA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-09-30 | 0.233 | 1 | 0.187 |
| 2021-06-30 | 0.252 | 1 | 0.254 |
| 2021-03-31 | 0.277 | 1 | 0.222 |
| 2020-12-31 | 0.301 | 1 | 0.242 |
| 2020-09-30 | 0.025 | 1 | -0.219 |
| 2020-06-30 | 0.116 | 1 | -0.137 |
XOMA Price Target
For more insight on analysts targets of XOMA, see our XOMA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $44.67 | Average Broker Recommendation | 1.67 (Moderate Buy) |
XOMA Stock Price Chart Interactive Chart >
XOMA Price/Volume Stats
| Current price | $20.85 | 52-week high | $32.08 |
| Prev. close | $21.24 | 52-week low | $15.68 |
| Day low | $20.55 | Volume | 9,600 |
| Day high | $21.26 | Avg. volume | 32,167 |
| 50-day MA | $20.01 | Dividend yield | N/A |
| 200-day MA | $19.62 | Market Cap | 238.75M |
XOMA Corporation (XOMA) Company Bio
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.
Latest XOMA News From Around the Web
Below are the latest news stories about XOMA CORP that investors may wish to consider to help them evaluate XOMA as an investment opportunity.
XOMA Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)EMERYVILLE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”), the Biotech Royalty Aggregator, today announced the Company has granted Owen Hughes, the Company’s newly appointed Executive Chairman, two separate non-qualified stock options to purchase: (i) 100,000 shares of the Company’s common stock at an exercise price of $18.66 per share (the “First Hughes Inducement Award”) and (ii) 75,000 shares of the Company’s common stock at an exercise pr |
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization StrategyOwen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today Jim Neal has retired as Chief Executive Officer and two finance and biotechnology industry veterans have joined in newly created executive leadership roles to drive the Company’s next phase of accelerated growth. Mr. Neal has resigned as a director |
XOMA Declares Quarterly Preferred Stock DividendsEMERYVILLE, Calif., Dec. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B |
XOMA (NASDAQ:XOMA) shareholders have endured a 39% loss from investing in the stock five years agoXOMA Corporation ( NASDAQ:XOMA ) shareholders should be happy to see the share price up 14% in the last month. But over... |
XOMA Acquires Royalty and Milestone License to Ebopiprant, a Preterm Labor Asset, Being Developed by OrganonXOMA assumes the rights to ebopiprant from ObsEva, including the Organon License, Patent Estate, and Merck KGaA, Darmstadt, Germany, license, for a $15 million outlay Potential to earn $475 million in development, regulatory, and sales milestones Low- to mid- teens royalties upon commercialization Expands XOMA’s portfolio into new therapeutic segment – women’s health EMERYVILLE, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), a biotech royalty aggregator playing a dist |
XOMA Price Returns
| 1-mo | 13.19% |
| 3-mo | 23.74% |
| 6-mo | -8.79% |
| 1-year | 2.01% |
| 3-year | -12.39% |
| 5-year | -38.59% |
| YTD | 13.32% |
| 2022 | -11.75% |
| 2021 | -52.75% |
| 2020 | 61.65% |
| 2019 | 115.81% |
| 2018 | -64.47% |
Continue Researching XOMA
Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...